Immuneering (NASDAQ:IMRX) Releases Earnings Results, Misses Estimates By $0.01 EPS

Immuneering (NASDAQ:IMRX) released its quarterly earnings results on Monday. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.01), Zacks reports.

Immuneering Stock Down 2.8 %

Shares of NASDAQ:IMRX traded down $0.04 during midday trading on Tuesday, reaching $1.22. 145,003 shares of the company were exchanged, compared to its average volume of 2,330,073. The firm has a market cap of $43.72 million, a PE ratio of -0.62 and a beta of -0.22. Immuneering has a fifty-two week low of $1.00 and a fifty-two week high of $3.83. The stock has a fifty day simple moving average of $1.46 and a two-hundred day simple moving average of $1.81.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Needham & Company LLC reissued a “buy” rating and set a $12.00 price objective on shares of Immuneering in a research note on Thursday, April 10th. Chardan Capital restated a “buy” rating and issued a $13.00 price target on shares of Immuneering in a report on Tuesday.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.